Gefitinib and erlotinib, first-generation EGFR-TKIs, were investigated for their efficacy for the treatment of lung adenocarcinomas with the G719X, L861Q, and S768I mutations in a multicenter study from Taiwan. The gene discussed is EGFR; the disease is lung adenocarcinoma.